Trials / Completed
CompletedNCT01786616
Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma
Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Catholic University, Italy · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in literature. The aim of this study was to verify whether homozygote for arginine-16 (ArgArg16) and homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Formoterol |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2010-04-01
- First posted
- 2013-02-08
- Last updated
- 2013-02-08
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01786616. Inclusion in this directory is not an endorsement.